Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA:600867)
China · Delayed Price · Currency is CNY 9.83
-0.15 (-1.50%)
Apr 28, 2026, 3:00 PM CST
SHA:600867 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,947 | 1,976 | 2,930 | 2,742 | 3,219 |
Other Revenue | - | 33.15 | 145.81 | 36.47 | 49.22 |
| 2,947 | 2,010 | 3,075 | 2,778 | 3,268 | |
Revenue Growth (YoY) | 46.66% | -34.66% | 10.69% | -14.98% | 12.99% |
Cost of Revenue | 874.5 | 547.46 | 621.05 | 628.13 | 586.99 |
Gross Profit | 2,073 | 1,462 | 2,454 | 2,150 | 2,681 |
Selling, General & Admin | 1,289 | 1,252 | 1,047 | 1,114 | 1,255 |
Research & Development | 167.12 | 99.3 | 104.96 | 146.71 | 166.86 |
Other Operating Expenses | 13.76 | 13.13 | 11.65 | 14.57 | 11.27 |
Operating Expenses | 1,470 | 1,349 | 1,184 | 1,268 | 1,435 |
Operating Income | 602.84 | 113.02 | 1,270 | 882.29 | 1,246 |
Interest Expense | - | -14.38 | -5.17 | -0.28 | - |
Interest & Investment Income | 1,180 | 130.82 | 103.61 | 942.66 | 304.32 |
Currency Exchange Gain (Loss) | - | 0.7 | 0.47 | 0 | 0.24 |
Other Non Operating Income (Expenses) | -113.13 | -1.14 | -1.65 | -0.88 | 0.33 |
EBT Excluding Unusual Items | 1,669 | 229.02 | 1,368 | 1,824 | 1,550 |
Gain (Loss) on Sale of Investments | 0.22 | 0.4 | 0.52 | 0.96 | -0.37 |
Gain (Loss) on Sale of Assets | -3.12 | -239.83 | -3.13 | -0.11 | -13.48 |
Asset Writedown | -189.16 | -80.68 | -7 | -1.74 | -11.53 |
Legal Settlements | - | -60.82 | - | - | - |
Other Unusual Items | - | 8.16 | 7.91 | 6.62 | 9.35 |
Pretax Income | 1,477 | -143.75 | 1,366 | 1,830 | 1,534 |
Income Tax Expense | 280.05 | -99.63 | 197.97 | 247.69 | 225.86 |
Earnings From Continuing Operations | 1,197 | -44.12 | 1,168 | 1,582 | 1,309 |
Minority Interest in Earnings | 21.86 | 1.4 | -0.09 | 0.06 | -0.34 |
Net Income | 1,219 | -42.72 | 1,168 | 1,582 | 1,308 |
Net Income to Common | 1,219 | -42.72 | 1,168 | 1,582 | 1,308 |
Net Income Growth | - | - | -26.17% | 20.92% | 40.69% |
Shares Outstanding (Basic) | 1,966 | 2,136 | 1,979 | 2,002 | 2,044 |
Shares Outstanding (Diluted) | 1,966 | 2,136 | 1,979 | 2,002 | 2,044 |
Shares Change (YoY) | -7.96% | 7.92% | -1.15% | -2.04% | 1.12% |
EPS (Basic) | 0.62 | -0.02 | 0.59 | 0.79 | 0.64 |
EPS (Diluted) | 0.62 | -0.02 | 0.59 | 0.79 | 0.64 |
EPS Growth | - | - | -25.32% | 23.44% | 39.13% |
Free Cash Flow | 171.53 | -108.99 | 513.4 | 370.21 | 579.62 |
Free Cash Flow Per Share | 0.09 | -0.05 | 0.26 | 0.18 | 0.28 |
Dividend Per Share | - | 0.250 | 0.250 | 0.500 | 0.300 |
Dividend Growth | - | - | -50.00% | 66.67% | 42.86% |
Gross Margin | 70.33% | 72.76% | 79.81% | 77.39% | 82.04% |
Operating Margin | 20.46% | 5.62% | 41.31% | 31.75% | 38.12% |
Profit Margin | 41.36% | -2.13% | 37.97% | 56.93% | 40.03% |
Free Cash Flow Margin | 5.82% | -5.42% | 16.69% | 13.32% | 17.74% |
EBITDA | 866.68 | 300.02 | 1,456 | 1,033 | 1,389 |
EBITDA Margin | 29.41% | 14.93% | 47.35% | 37.20% | 42.51% |
D&A For EBITDA | 263.83 | 187 | 185.87 | 151.17 | 143.65 |
EBIT | 602.84 | 113.02 | 1,270 | 882.29 | 1,246 |
EBIT Margin | 20.46% | 5.62% | 41.31% | 31.75% | 38.12% |
Effective Tax Rate | 18.96% | - | 14.49% | 13.54% | 14.72% |
Revenue as Reported | - | 2,010 | 3,075 | 2,778 | 3,268 |
Advertising Expenses | - | 93.24 | 63.59 | 46.79 | 143.61 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.